Cardiac Failure Clinical Trial
— Pro-ICARDOfficial title:
Pronostic Value of Endothelial Dysfunction in Heart Failure
The main objective is to evaluate the pronostic value of endothelial dysfonction in acute heart failure on a combined criteria associating cardiovascular mortality, nex hospitalisation for decompensated heart failure, cardiac graft or ventricular assistance 2 month and 1 year before acute heart failure.
Status | Terminated |
Enrollment | 7 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 81 Years |
Eligibility |
Inclusion Criteria: - patients hospitalized for acute heart fialure with Left Ventricular Ejection Fraction (LVEF) < 45 % on echocardiography Exclusion Criteria: - Informed consent form not signed - Cardiogenic, septic or hemorragic shock - Acute coronary syndrom with elevated troponin - valvular surgery or aorto-coronary graft during next 3 months - Cancer - Pregnancy - life expectancy over than 1 year - chronic renal impairment |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Besancon |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MR Proadrenomedulline | 6 months | No | |
Primary | catecholamins | 6 months | No | |
Primary | late endothelial progenitors | 6 months | No | |
Primary | Peripheral tissular perfusion | Near infra-red spectroscopy | 6 months | No |
Primary | mortality | 6 months | No | |
Primary | hospitalisation | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03799133 -
Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery
|
N/A | |
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Terminated |
NCT02205411 -
Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation
|
N/A | |
Completed |
NCT02524574 -
Tomography Positron Emission Assessment of the Impact of Cardiac Rehabilitation on Coronary Endothelial Function in Cardiac Failure
|
N/A | |
Active, not recruiting |
NCT03841084 -
Blend to Limit Oxygen in ECMO: A Randomised Controlled Registry Trial
|
Phase 2 | |
Terminated |
NCT02459054 -
Syncardia 50cc TAH-t as a Bridge to Transplant
|
N/A | |
Completed |
NCT04599816 -
Levosimendan Administration in Pulmonary Hypertension
|
N/A | |
Recruiting |
NCT05761639 -
Physical Exercise and Telephone Follow-up Mediated by Telerehabilitation
|
N/A | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT03357731 -
A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function
|
Phase 2 | |
Completed |
NCT02331264 -
Cardiac Assessment of Patients With Hip Implants
|
N/A | |
Terminated |
NCT01921829 -
Protocolized Diuretic Strategy in Cardiorenal Failure
|
Phase 4 | |
Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|
||
Recruiting |
NCT03197792 -
Perioperative Portal Vein Pulsatility as a Postoperative Prognostic Indicator in Pulmonary Endarterectomy
|
N/A | |
Completed |
NCT03515980 -
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
|
Phase 1 | |
Completed |
NCT03212898 -
Pharmacist Interventions in Rural Elderly Warfarin Patients
|
N/A | |
Completed |
NCT03243604 -
cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study
|
||
Completed |
NCT06330103 -
Efficacy of AI EF Screening by Using Smartphone Application Recorded PLAX View Cardiac Ultrasound Video Clips
|
N/A | |
Completed |
NCT02660385 -
Insomnia Self-Management in Heart Failure
|
N/A | |
Withdrawn |
NCT02669134 -
CRT Improved Clinical Response UK Trial
|
Phase 3 |